Top Page
Tristel
(LSE:TSTL)
Tristel (TSTL) vs. S&P 500 (SPY)
Tristel Business Overview & Revenue Model
Tristel Financial Statement Overview
| Breakdown | ||||
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 41.93M | 36.01M | 31.12M | 31.00M | 31.68M | Gross Profit |
| 30.87M | 29.18M | 24.66M | 24.74M | 25.25M | EBIT |
| 7.05M | 5.28M | 4.20M | 4.76M | 6.80M | EBITDA |
| 10.01M | 7.84M | 4.46M | 6.70M | 9.30M | Net Income Common Stockholders |
| 6.49M | 4.46M | 987.00K | 3.66M | 5.10M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 11.79M | 9.54M | 8.88M | 8.09M | 6.21M | Total Assets |
| 44.11M | 41.37M | 38.74M | 39.93M | 40.93M | Total Debt |
| 5.86M | 5.18M | 5.81M | 5.91M | 6.00M | Net Debt |
| -275.00K | -1.93M | -3.07M | -2.19M | -210.00K | Total Liabilities |
| 11.70M | 10.68M | 9.75M | 9.85M | 12.47M | Stockholders Equity |
| 32.41M | 30.68M | 28.98M | 30.08M | 28.46M |
| Cash Flow | Free Cash Flow | |||
| 10.06M | 6.07M | 4.35M | 4.71M | 4.61M | Operating Cash Flow |
| 11.20M | 8.49M | 5.55M | 6.48M | 6.99M | Investing Cash Flow |
| -5.40M | -4.84M | -1.20M | -1.77M | -2.97M | Financing Cash Flow |
| -6.57M | -5.44M | -3.62M | -2.83M | -2.02M |
Tristel Technical Analysis
Tristel Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | £8.21B | 25.39 | 7.78% | 2.92% | 1.85% | 51.77% | |
75 Outperform | £139.53M | 22.66 | 19.61% | 4.77% | 10.32% | 1.25% | |
75 Outperform | £9.02B | 31.37 | 16.90% | 0.93% | 11.94% | 20.48% | |
68 Neutral | £641.02M | 37.26 | 3.58% | 8.08% | -5.21% | -72.13% | |
66 Neutral | £1.93B | 3.97 | 21.80% | 6.66% | -15.51% | 200.70% | |
63 Neutral | £3.69B | 23.27 | 6.84% | 4.13% | -3.92% | -7.32% | |
48 Neutral | $6.36B | 1.28 | -45.04% | 2.64% | 19.24% | 1.69% |
Tristel Corporate Events
Tristel plc has submitted additional information to the FDA for its Tristel OPH, a high-level disinfectant foam for ophthalmic devices, with an expected decision by June 2025. The approval could significantly impact ophthalmic disinfection practices in North America, addressing inefficiencies and improving safety standards. The company aims to leverage this opportunity to enhance its market presence and reach key decision-makers at the upcoming APIC conference.
Spark’s Take on GB:TSTL Stock
According to Spark, TipRanks’ AI Analyst, GB:TSTL is a Outperform.
Tristel’s strong financial health and positive corporate events are the primary drivers of its score, indicating a promising outlook for growth and stability. However, bearish technical indicators suggest potential short-term challenges. The balanced valuation adds support, making Tristel a strong candidate for long-term investment, especially considering the company’s strategic initiatives and insider confidence.
To see Spark’s full report on GB:TSTL stock, click here.
Tristel plc announced the publication of a poster by the Mayo Clinic at the AORN Global Surgical Conference & Expo, detailing the successful trial of Tristel ULT™, a high-level disinfection foam for ultrasound probes. The trial, which involved 11 Mayo Clinic staff members and 189 ultrasound probes, reported no surgical site infections and highlighted the foam’s effectiveness, efficiency, and cost-effectiveness. This development follows recognition by the AAMI and ANSI of chlorine dioxide foam as a novel disinfection method and adds to the growing number of US case studies supporting Tristel ULT™. Tristel’s sales in North America are experiencing strong growth, with over 200,000 disinfection procedures conducted this financial year, reflecting increasing adoption and customer engagement.
Spark’s Take on GB:TSTL Stock
According to Spark, TipRanks’ AI Analyst, GB:TSTL is a Neutral.
Tristel’s overall score reflects its strong financial health and positive corporate events, tempered by bearish technical indicators. The balanced valuation provides an additional support to the stock’s prospects. Strategic growth initiatives and insider confidence bolster the company’s future outlook.
To see Spark’s full report on GB:TSTL stock, click here.
Tristel plc announced that its Chief Financial Officer, Liz Dixon, purchased 5,000 ordinary shares of the company at a price of 291.99 pence per share, increasing her beneficial interest to 155,000 shares, which represents 0.32% of the company’s total issued share capital. This transaction reflects confidence in the company’s operations and could positively impact stakeholder perception, reinforcing Tristel’s strong positioning in the infection prevention industry.
Tristel plc announced that its CEO, Matthew Sassone, has purchased 3,500 ordinary shares of the company at 310 pence per share, increasing his beneficial interest to 0.007% of the total issued share capital. This move may signal confidence in the company’s future prospects and could positively influence stakeholder perceptions, reinforcing the company’s market position in the infection prevention industry.
Tristel PLC reported strong interim results for the six months ending December 2024, with an 8% revenue increase to £22.6 million and a 19% rise in adjusted profit before tax to £4.9 million. The company remains debt-free and cash-generative, maintaining a progressive dividend policy. Tristel’s expansion efforts are centered on geographic growth, particularly in the USA, where they anticipate significant opportunities. Key operational highlights include the successful transition of the CEO and a strategic FDA filing for a new disinfectant product, indicating promising growth prospects and industry positioning.
Tristel plc has issued 10,250 new ordinary shares following the exercise of employee share options, bringing the total number of shares and voting rights to 47,702,343. This move facilitates trading of these shares on the London Stock Exchange’s AIM, allowing shareholders to adjust their interests under FCA’s regulations, potentially impacting shareholder engagement and company transparency.
Tristel plc announced the grant of 127,468 new share options to two directors under its Long Term Incentive Plan, aiming to align director performance with shareholder interests. The performance targets for these options are based on earnings per share and total shareholder return, which could impact the company’s operational focus and shareholder value in the long term.
Tristel plc has scheduled briefings for its interim results for the six-month period ending December 31, 2024. These events, to be held on February 24, 2025, include an analyst briefing in London and two investor presentations, one online and another in-person, to cater to both existing and potential shareholders. This initiative reflects Tristel’s commitment to transparency and stakeholder engagement, potentially bolstering its market position and investor confidence.